Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic Priming and Pembrolizumab in Pancreatic Cancer
NCT06381154Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Dec 2024
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of verteporfin and pembrolizumab in pancreatic cancer (PC), sponsored by Mayo Clinic. Primary endpoint: Overall Response Rate at 2 years. Started Dec 2024; status: active, not recruiting.
02
Drugs
verteporfinpembrolizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06381154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381154.